Biologic Therapy in Chronic Obstructive Pulmonary Disease

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Chronic obstructive pulmonary disease (COPD) is common worldwide. The predominant cause in most COPD is environmental exposure to toxicants. The inflammatory processes in COPD are multifactorial, complex, and interacting, leading to many potential therapeutic targets. Although most typically associated with neutrophilic/macrophagic inflammation (type 1), it is now known that COPD can also be associated with eosinophilic inflammation (type 2), particularly in exacerbations. Accordingly, there is an active program of investigation of highly selective biologic therapeutic agents in the management of COPD. This review summarizes clinical trials of the use of these novel agents in the management of COPD.

Original languageEnglish (US)
Pages (from-to)345-355
Number of pages11
JournalImmunology and Allergy Clinics of North America
Issue number2
StatePublished - May 1 2017


  • Biologic therapy
  • COPD
  • Exacerbation
  • IL-5
  • TNF-alpha

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Biologic Therapy in Chronic Obstructive Pulmonary Disease'. Together they form a unique fingerprint.

Cite this